All In Biotech

Drug Trial Radar · NCT00835510

Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

Last checked: Nov 19, 2026Latest source record: Feb 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 548 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

548

Actual

Start

Jun 2008

Primary completion

Oct 2008

Study completion Dec 2008

Sponsor

Sponsor type
Industry
First posted
Feb 3, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show the superiority of the active treatments over that of the placebo (vehicle).

Conditions

  • Tinea Pedis

Interventions

  • Butenafine cream 1% manufactured by TaroDrug

    Treatment applied to affected area twice daily for 7 days

  • Lotrimin Ultra (butenafine) 1%Drug

    Treatment applied to affected area twice daily for 7 days

  • Butenafine Vehicle manufactured by TaroDrug

    Treatment applied to affected area twice daily for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic Cure - Superiority AnalysisTime frame: 42 days
  2. Therapeutic Cure Non-Inferiority Comparison of Butenafine Cream and Lotrimin UltraTime frame: 42 days

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigator Site

    Burbank, California

  • Investigator Site

    San Diego, California

  • Investigator Site

    Miami, Florida

  • Investigator Site

    Martinez, Georgia

  • Investigator Site

    Stockbridge, Georgia

  • Investigator Site

    Clinton Township, Michigan

  • Investigator Site

    Hickory, North Carolina

  • Investigator Site

    Raleigh, North Carolina

  • Investigator Site

    Salisbury, North Carolina

  • Investigator Site

    Sylvania, Ohio

  • Investigator Site

    Simpsonville, South Carolina

  • Investigator Site

    Bristol, Tennessee

  • Investigator Site

    Nashville, Tennessee

  • Investigator Site

    College Station, Texas

  • Investigator Site

    Houston, Texas

  • Investigator Site

    San Antonio, Texas

  • Investigator Site

    Belize City, Belize

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.